Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies
US10227400B2 · kind B2 · utility
9Cited by
48References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 19, 2017 |
| Grant date | Mar 12, 2019 |
| Priority date | — |
| Expiry date | Sep 19, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.